Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ClearPoint Neuro ( (CLPT) ) has provided an update.
On May 13, 2026, ClearPoint Neuro reported first-quarter 2026 revenue of $12.1 million, up 43% year over year, including 16% organic growth and contribution from the recently acquired IRRAflow portfolio. The company’s activated installed base now spans more than 175 global centers, while gross margin expanded to 64% and cash and cash equivalents stood at $35.6 million as of March 31, 2026.
Neurosurgery navigation, therapy and access revenue rose 80% to $5.9 million, aided by IRRAflow sales and the rollout of 3.0 operating room navigation software, and capital equipment and software revenue climbed 177% to $1.4 million on increased placements of navigation, IRRAflow and Prism laser systems. Management highlighted integration-driven revenue and cost synergies from the IRRAS acquisition, ongoing clinical and regulatory progress with more than 60 biopharma partners, international expansion including Canada and Asia-Pacific, and reiterated a 2026 revenue outlook of $52 million to $56 million, while noting higher operating expenses and cash burn tied to the enlarged cost base.
The most recent analyst rating on (CLPT) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
Spark’s Take on CLPT Stock
According to Spark, TipRanks’ AI Analyst, CLPT is a Neutral.
The score is held down primarily by weak financial quality (large losses, heavier leverage, and increased cash burn) and bearish technical trend signals. Partially offsetting these are a more positive earnings-call setup with strong 2026 revenue guidance and sustained ~61% gross margins, while valuation remains challenged due to negative earnings and no dividend support.
To see Spark’s full report on CLPT stock, click here.
More about ClearPoint Neuro
ClearPoint Neuro, Inc. is a device, cell and gene therapy-enabling company focused on precise navigation to the brain and spine for both clinical and preclinical use. Its flagship ClearPoint Neuro Navigation System, which has FDA clearance and a CE mark, supports MRI and other image-guided neurosurgical workflows and is deployed with healthcare and research centers across North America, Europe, Asia and South America.
The company also provides preclinical development services and controlled drug and device delivery solutions, partnering with pharmaceutical and biotech firms, academic institutions and contract research organizations. Thousands of procedures have been performed using its technology, backed by a field-based clinical specialist team that supports customers and partners worldwide in central nervous system therapeutic delivery.
Average Trading Volume: 741,914
Technical Sentiment Signal: Hold
Current Market Cap: $379M
Find detailed analytics on CLPT stock on TipRanks’ Stock Analysis page.